Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Paul Houle

Neurological Surgery Hyannis, MA Medical Doctor

NPI 1184624330 CMS profile 7934

46 North St, Hyannis, MA 02601

Open in the dashboard

General payments

$773,960

689 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Paul Houle of Hyannis, MA is reported in the CMS Open Payments database as having received $773,960 across 689 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $116,444 106
2024 General $155,841 153
2023 General $95,167 84
2022 General $97,608 96
2021 General $80,789 112
2020 General $103,505 99
2019 General $124,607 39

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Houle
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Paul Houle were reported at $116,444. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Paul Houle Neurological Surgery median Middle half National median
2019 $124,607 $582 $138–$3,006 $163
2020 $103,505 $294 $76–$2,174 $114
2021 $80,789 $387 $105–$2,432 $132
2022 $97,608 $542 $139–$2,989 $149
2023 $95,167 $534 $145–$2,697 $160
2024 $155,841 $574 $155–$3,046 $164
2025 $116,444 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Integrity Implants Inc. $229,722 166 payments
  2. Joimax, Inc. $203,696 14 payments
  3. Integrity Implants Inc $200,929 293 payments
  4. Arthrex, Inc. $117,610 105 payments
  5. Alphatec Spine, Inc $9,003 22 payments
  6. Kuros Biosciences USA, Inc $7,404 11 payments
  7. Kairos Surgical Inc $1,148 10 payments
  8. Relievant Medsystems, Inc. $891 13 payments
  9. Spineart USA Inc $590 1 payment
  10. Medtronic, Inc. $383 7 payments
  11. Other $2,584 47 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $408,038 99 payments
  2. Travel and Lodging $246,644 247 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $68,233 14 payments
  4. Royalty or License $27,696 15 payments
  5. Food and Beverage $21,615 310 payments
  6. Entertainment $1,690 3 payments
  7. Gift $44 1 payment
Products named General payments · program years 2019–2025
  1. FlareHawk $296,427 183 payments
  2. FlareHawk 7 ENDO $24,145 42 payments
  3. FlareHawk 7 $7,673 15 payments
  4. MAGNETOS $7,356 9 payments
  5. Other - Miscellaneous $6,501 9 payments
  6. REMI $3,000 3 payments
  7. Xvision $1,609 20 payments
  8. Intracept Pain $739 10 payments
  9. Intracept Pain $540 7 payments
  10. IRRASflow $283 1 payment
  11. Other $4,479 77 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

142

Median for Neurosurgery: 83

Drug cost

$398

Median for Neurosurgery: $872

Branded share of claims

0%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone Hcl Generic 73 $225
Tizanidine Hcl Generic 44 $95
Methylprednisolone Generic 11 $65
Tramadol Hcl Generic 14 $12

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 65 billing codes

Paid by Medicare

$233,892

Medicare's payments for the services billed

Medicare patients

393

Average age 75

Services billed

1,013

193 women, 200 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 31%
Depression 27%
Chronic kidney disease 22%
Osteoporosis 21%
Diabetes 20%
Atrial fibrillation 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

689 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record